Display options
Cite
Zou J, Feng H, Sood R, et al. Biocompatibility of Liposome Nanocarriers in the Rat Inner Ear After Intratympanic Administration. Nanoscale Res Lett. 2017;12(1):372doi: 10.1186/s11671-017-2142-5.
Zou, J., Feng, H., Sood, R., Kinnunen, P. K. J., & Pyykko, I. (2017). Biocompatibility of Liposome Nanocarriers in the Rat Inner Ear After Intratympanic Administration. Nanoscale research letters, 12(1), 372. https://doi.org/10.1186/s11671-017-2142-5
Zou, Jing, et al. "Biocompatibility of Liposome Nanocarriers in the Rat Inner Ear After Intratympanic Administration." Nanoscale research letters vol. 12,1 (2017): 372. doi: https://doi.org/10.1186/s11671-017-2142-5
Zou J, Feng H, Sood R, Kinnunen PKJ, Pyykko I. Biocompatibility of Liposome Nanocarriers in the Rat Inner Ear After Intratympanic Administration. Nanoscale Res Lett. 2017 Dec;12(1):372. doi: 10.1186/s11671-017-2142-5. Epub 2017 May 25. PMID: 28549377; PMCID: PMC5445035.
Copy Download .nbib Format: NLM
Share it on

Nanoscale Res Lett. 2017 Dec;12(1):372. doi: 10.1186/s11671-017-2142-5. Epub 2017 May 25.

Biocompatibility of Liposome Nanocarriers in the Rat Inner Ear After Intratympanic Administration.

Nanoscale research letters

Jing Zou, Hao Feng, Rohit Sood, Paavo K J Kinnunen, Ilmari Pyykko

Affiliations

  1. Department of Otolaryngology Head and Neck Surgery, Center for Otolaryngology-Head and Neck Surgery of Chinese PLA, Changhai Hospital, Second Military Medical University, Changhai Road #168, 200433, Shanghai, China. [email protected].
  2. Hearing and Balance Research Unit, Field of Oto-laryngology, School of Medicine, University of Tampere, Tampere, Finland. [email protected].
  3. Hearing and Balance Research Unit, Field of Oto-laryngology, School of Medicine, University of Tampere, Tampere, Finland.
  4. Present Address: Department of Otorhinolaryngology/Head and Neck Surgery, University Medical Center Groningen, Groningen, The Netherlands.
  5. Helsinki Biophysics and Biomembrane Group, Department of Biomedical Engineering and Computational Sciences, Aalto University, Espoo, Finland.

PMID: 28549377 PMCID: PMC5445035 DOI: 10.1186/s11671-017-2142-5

Abstract

Liposome nanocarriers (LPNs) are potentially the future of inner ear therapy due to their high drug loading capacity and efficient uptake in the inner ear after a minimally invasive intratympanic administration. However, information on the biocompatibility of LPNs in the inner ear is lacking. The aim of the present study is to document the biocompatibility of LPNs in the inner ear after intratympanic delivery. LPNs with or without gadolinium-tetra-azacyclo-dodecane-tetra-acetic acid (Gd-DOTA) were delivered to the rats through transtympanic injection. The distribution of the Gd-DOTA-containing LPNs in the middle and inner ear was tracked in vivo using MRI. The function of the middle and inner ear barriers was evaluated using gadolinium-enhanced MRI. The auditory function was measured using auditory brainstem response (ABR). The potential inflammatory response was investigated by analyzing glycosaminoglycan and hyaluronic acid secretion and CD44 and TLR2 expression in the inner ear. The potential apoptosis was analyzed using terminal transferase (TdT) to label the free 3'OH breaks in the DNA strands of apoptotic cells with TMR-dUTP (TUNEL staining). As a result, LPNs entered the inner ear efficiently after transtympanic injection. The transtympanic injection of LPNs with or without Gd-DOTA neither disrupted the function of the middle and inner ear barriers nor caused hearing impairment in rats. The critical inflammatory biological markers in the inner ear, including glycosaminoglycan and hyaluronic acid secretion and CD44 and TLR2 expression, were not influenced by the administration of LPNs. There was no significant cell death associated with the administration of LPNs. The transtympanic injection of LPNs is safe for the inner ear, and LPNs may be applied as a drug delivery matrix in the clinical therapy of sensorineural hearing loss.

Keywords: Animal; Biological Response; Drug Delivery; Inner Ear; Liposome; Nanomaterial

References

  1. Eur Arch Otorhinolaryngol. 2013 Sep;270(9):2403-15 - PubMed
  2. Nat Rev Cancer. 2004 Jul;4(7):528-39 - PubMed
  3. Otol Neurotol. 2012 Jun;33(4):666-73 - PubMed
  4. Nanomedicine (Lond). 2014 Jul;9(14):2143-55 - PubMed
  5. J Mammary Gland Biol Neoplasia. 2001 Jul;6(3):287-97 - PubMed
  6. J Med Assoc Thai. 2009 Sep;92(9):1150-8 - PubMed
  7. Arthritis Rheum. 2010 Jul;62(7):2004-12 - PubMed
  8. Infect Immun. 2007 Jul;75(7):3361-72 - PubMed
  9. Neuroreport. 2004 Jul 19;15(10):1597-600 - PubMed
  10. ACS Biomater Sci Eng. 2015 Jul 13;1(7):481-493 - PubMed
  11. Laryngoscope. 2003 May;113(5):797-801 - PubMed
  12. J Cell Sci. 2004 Jan 26;117(Pt 3):373-80 - PubMed
  13. Otol Neurotol. 2010 Aug;31(6):867-74 - PubMed
  14. Eur Arch Otorhinolaryngol. 2015 Oct;272(10):2629-42 - PubMed
  15. Nanoscale Res Lett. 2016 Dec;11(1):240 - PubMed
  16. Toxicol Lett. 2008 Jul 10;179(3):130-9 - PubMed
  17. Artif Organs. 2012 Feb;36(2):178-84 - PubMed
  18. Science. 2002 Apr 5;296(5565):155-8 - PubMed
  19. Int J Nanomedicine. 2012;7:49-60 - PubMed
  20. Nanomedicine (Lond). 2012 Sep;7(9):1339-54 - PubMed
  21. Clin Pharmacokinet. 2006;45(12):1153-76 - PubMed
  22. J Nanobiotechnology. 2010 Dec 18;8:32 - PubMed
  23. Nat Rev Mol Cell Biol. 2003 Jan;4(1):33-45 - PubMed
  24. J Nanobiotechnology. 2015 Jan 27;13:5 - PubMed
  25. Ann Otol Rhinol Laryngol. 2012 Feb;121(2):119-28 - PubMed
  26. J Nanobiotechnology. 2014 Dec 03;12:52 - PubMed
  27. Int J Nanomedicine. 2014 Feb 19;9:1005-23 - PubMed

Publication Types